Nathan Shores, MD
Gastroenterology · Charleston, SCNPI 1417173378
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $205,931 of the $217,029 with a category attached, or 94.9%. AbbVie accounts for 71.5% of it on its own, with 27 other manufacturers making up the rest. Among gastroenterology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $591.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$155K
- Madrigal Pharmaceuticals$37K
- Gilead$15K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$9K
- Takeda Pharmaceuticals U.S.A., Inc.$233
- Phathom Pharmaceuticals, Inc.$133
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$205,93195%
- Travel & lodging$4,1662%
- Food & beverage$6,8553%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 186 | $155,096 |
| Madrigal Pharmaceuticals | 24 | $36,844 |
| Gilead | 22 | $14,929 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $8,566 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $233 |
| Phathom Pharmaceuticals, Inc. | 7 | $133 |
| Sandoz | 8 | $131 |
| Celltrion USA Inc. | 6 | $125 |
| Regeneron Healthcare Solutions, Inc. | 4 | $100 |
| Ardelyx, Inc. | 6 | $100 |
| Sanofi | 3 | $95 |
| Johnson & Johnson | 4 | $83 |
| Aimmune Therapeutics, Inc. | 4 | $76 |
| Lilly USA, LLC | 4 | $67 |
| Novo Nordisk | 3 | $66 |
| Pfizer | 4 | $62 |
| Ironwood Pharmaceuticals, Inc | 3 | $48 |
| Medtronic | 2 | $45 |
| Bristol Myers Squibb | 2 | $41 |
| Boston Scientific | 2 | $40 |
| Merck | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Mirum Pharmaceuticals, Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| QOL Medical, LLC | 1 | $13 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$217,029 in reported general payments places this provider in the 95th percentile of 259 gastroenterology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 56 | $182,564 |
| LinzessLinaclotide | 44 | $60,668 |
| ZenpepLipase/Protease/Amylase | 13 | $49,897 |
| RezdiffraResmetirom | 11 | $42,858 |
| MounjaroTirzepatide | 27 | $34,850 |
| Dexlansoprazole DrDexlansoprazole | 39 | $15,079 |
| MovantikNaloxegol Oxalate | 15 | $13,352 |
| Mesalamine | 23 | $12,400 |
| Ursodiol | 79 | $11,927 |
| TrulancePlecanatide | 14 | $11,749 |
| Omeprazole | 430 | $7,671 |
| Entecavir | 19 | $5,846 |
| Famotidine | 137 | $2,385 |
| Pantoprazole Sodium | 139 | $2,166 |
| Dicyclomine Hcl | 66 | $1,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $8,566 | $194,31370 claims |
| AbbVieLinzess | $155,096 | $60,66844 claims |
| Aimmune Therapeutics, Inc.Zenpep | $76 | $49,89713 claims |
| Madrigal PharmaceuticalsRezdiffra | $36,844 | $42,85811 claims |
| Lilly USA, LLCMounjaro | $67 | $34,85027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 gastroenterology providers in South Carolina.
Other gastroenterology in Charleston
- Erin ForsterCharleston$788K
- Mark DeleggeCharleston$568K
- Alejandro SuarezCharleston$210K
- Peter CottonCharleston$193K
- David KochCharleston$48K
- Derek FeussnerCharleston$35K
- Darin DufaultCharleston$33K
- John LitchfieldCharleston$23K
- James SchnellCharleston$12K
- Michael SagatelianCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.